Research programme: small molecule oncology therapeutics - AVEO/OSI Pharmaceuticals

Drug Profile

Research programme: small molecule oncology therapeutics - AVEO/OSI Pharmaceuticals

Alternative Names: OSI-296

Latest Information Update: 14 Jan 2014

Price : $50

At a glance

  • Originator AVEO Pharmaceuticals; OSI Pharmaceuticals
  • Developer Astellas Pharma
  • Class Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Aug 2013 Preclinical development is ongoing in USA
  • 29 May 2012 AVEO Pharmaceuticals is now called AVEO Oncology
  • 02 Dec 2010 OSI Pharmaceuticals exercises license expansion option under the licensing agreement with AVEO Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top